11.03.2020 DEINOVE passes the 2nd milestone of the AGIR program and receives €1.5m from Bpifrance The AGIR program, supported by the French Investments for the Future program, aims to accelerate new antibiotics discovery to tackle the...
19.02.2020 DEINOVE expands its range of cosmetic active ingredients Its second innovative carotenoid has the particularity of absorbing blue light, which is responsible for premature skin ageing, the...
06.02.2020 Sharon Laboratories capitalizes on Deinove to sustain its development activities The signed Memorandum of Understanding (MoU) covers the development and marketing of an exclusive range of bio-based ingredients for...
27.01.2020 Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections The Phase II clinical trial aims to evaluate the efficacy, safety and pharmacokinetics of DNV3837 in patients with Clostridioides difficile...
22.01.2020 New industrial-scale production of Phyt-N-Resist® to supply the market DEINOVE launches the production of a new batch of Phyt-N-Resist® to meet the needs of its distributors and future customers. Several...
20.01.2020 DEINOVE announces its financial calendar for 2020 DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...
09.12.2019 DEINOVE and ESPCI Paris obtain funding from the ANR to develop the Deinodrop technology The Deinodrop technology will be co-developed by ESPCI and DEINOVE to accelerate the discovery and identification of bacteria producing new...
06.12.2019 Evolution in DEINOVE's governance Emmanuel PETIOT will resign as Chief Executive Officer ("CEO") as of December 31, 2019 Dr. Charles WOLER, Chairman of the Board of...
04.11.2019 New product preview at In-Cosmetics Asia 2019: a second innovative carotenoid from DEINOVE This new carotenoid has the particularity of absorbing blue light, which is responsible for premature skin ageing, the appearance of skin...
15.10.2019 DEINOVE selected for a presentation at BARDA Industry Day 2019 in Washington DC DEINOVE will present DNV3837/DNV3681, its antibiotic candidate targeting both urgent threats to public health and bioterrorism pathogens...